Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from an ongoing open-label extension phase of a global Phase 2 clinical trial (NCT04879628), which showed that brain lesions […]

The post CMSC 2026: Trial data show frexalimab benefits lasting 3 years appeared first on Multiple Sclerosis News Today.

Source: multiplesclerosisnewstoday.com